Clinical Trial Update: A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers [Phase 2]

View source ↗

Summary

Phase 2 study of Zanidatamab (ZW25) in advanced or metastatic HER2-amplified biliary tract cancers completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Zanidatamab (ZW25) (zanidatamab)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: HER2-amplified Biliary Tract Cancers | Phase 2 | Status: COMPLETED | Results posted: 2024-08-21